Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Study of DA-9801 to Treat Diabetic Neuropathy

ClinicalTrials.gov ID: NCT01822925

Public ClinicalTrials.gov record NCT01822925. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 3:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Randomized, Double-Blind, Parallel Group, Dose-Ranging, Placebo-Controlled Study to Assess the Safety And Effectiveness Of DA-9801 in the Treatment of Subjects With Diabetic Neuropathy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

To evaluate the effectiveness of DA-9801 at 300mg, 600mg, 900mg and placebo, in reducing pain in subjects with diabetic neuropathic pain compared to their baseline values.

Study identification

NCT ID
NCT01822925
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
NeuroBo Pharmaceuticals Inc.
Industry
Enrollment
128 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 31, 2013
Primary completion
Dec 31, 2014
Completion
Dec 31, 2014
Last update posted
Mar 19, 2020

2013 – 2015

United States locations

U.S. sites
14
U.S. states
10
U.S. cities
13
Facility City State ZIP Site status
Center for United Research, Inc. Lakewood California 90712
Diablo Clinical Research Walnut Creek California 94598-3347
Clinical Research Consulting, LLC Milford Connecticut 06460
PAB Clinical Research Brandon Florida 33511
Metabolic Research Institute, Inc. West Palm Beach Florida 33401
Johns Hopkins University Baltimore Maryland 21205
Novex Clinical Research, Inc. New Bedford Massachusetts 02740
Albany Medical Center Albany New York 12208
Coastal Carolina Research Center Mt. Pleasant South Carolina 29464
KRK Research Dallas Texas 75230
North Texas Endocrine Center Dallas Texas 75231
Houston Foot & Ankle Care Houston Texas 77074
Wasatch Clinical Research Salt Lake City Utah 84107
Rainier Clinical Research Center, Inc. Renton Washington 98057

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01822925, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 19, 2020 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01822925 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →